| Symbol | NTRA |
|---|---|
| Name | NATERA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 13011 MCCALLEN PASS,BUILDING A SUITE 100, AUSTIN, Texas, 78753, United States |
| Telephone | +1 650 980-9190 |
| Fax | — |
| — | |
| Website | https://www.natera.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001604821 |
| Description | Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Nateras array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mothers blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result. Additional info from NASDAQ: |
2026-06-12 20:42
📋 MATTHEW RABINOWITZ (Director) plans to sell 100K shares of NATERA, INC (at $219.23 each, total $21.9M) Filed: Jun 12, 2026 | ID: 006014
Read more
2026-06-10 01:05
Marcus Gail Boxer 🟡 adjusted position in 11.0K shares (1 derivative) of Natera, Inc. (NTRA) at $218.81 ($2.9M) Transaction Date: Jun 05, 2026 | Filing ID: 000004
Read more
2026-06-09 19:05
New Form 3 - Natera, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001474056-26-000004 <b>Size:</b> 3 KB
Read more
2026-06-06 01:05
Chapman Steven Leonard 🔴 sold 41.1K shares of Natera, Inc. (NTRA) at $226.97 ($9.1M) Transaction Date: Jun 04, 2026 | Filing ID: 000013
Read more
2026-06-05 21:15
📋 GAIL MARCUS (Director) plans to sell 11K shares of NATERA, INC. (at $217.21 each, total $2.4M) Filed: Jun 05, 2026 | ID: 005722
Read more
2026-06-04 21:03
📋 STEVEN L CHAPMAN (Officer) plans to sell 41K shares of NATERA, INC. (at $221.03 each, total $9.1M) Filed: Jun 04, 2026 | ID: 005671
Read more
2026-06-04 12:00
Natera - Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
Read more
2026-06-04 12:00
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
Read more
2026-06-04 01:05
Moshkevich Solomon 🔴 sold 3.0K shares of Natera, Inc. (NTRA) at $220.67 Transaction Date: Jun 01, 2026 | Filing ID: 000015
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07292285 | The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. | — | Cancer of the Rectum | Withdrawn | 2026-10-01 | 2030-06-30 | ClinicalTrials.gov |
| NCT07565857 | Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa G… | Na | Gastric-Esophageal Cancer | Not_Yet_Recruiting | 2026-09-01 | 2034-09-01 | ClinicalTrials.gov |
| NCT07401316 | Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors | Na | Germ Cell Cancer Metastatic | Recruiting | 2026-06-03 | 2032-12-01 | ClinicalTrials.gov |
| NCT07340567 | Personalizing Chemotherapy Selection After Surgery for Patients With Stage III … | Phase3 | Colorectal Cancer | Not_Yet_Recruiting | 2026-05-01 | 2035-11-01 | ClinicalTrials.gov |
| NCT07339384 | Signatera Assessment in Early-Stage Endometrial Cancer | Na | Endometrial Cancer | Not_Yet_Recruiting | 2026-05-01 | 2034-05-01 | ClinicalTrials.gov |
| NCT07290985 | AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Ade… | Phase2 | Gastroesophageal Adenocarcinoma | Not_Yet_Recruiting | 2026-05-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for… | Phase2 | Diffuse Large B Cell Lymphoma | Not_Yet_Recruiting | 2026-05-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | Na | Breast Neoplasms | Recruiting | 2026-03-24 | 2037-12-30 | ClinicalTrials.gov |
| NCT07195071 | Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditar… | Na | Hereditary Cancer Syndrome | Recruiting | 2026-02-12 | 2028-12-31 | ClinicalTrials.gov |
| NCT07183319 | Circulating Tumor DNA Response In Urothelial Cancer | Phase2 | Urothelial Carcinoma | Recruiting | 2026-01-19 | 2029-03-01 | ClinicalTrials.gov |
| NCT05756088 | Determining the Association of Microvascular Disease as Assessed by PET and Gra… | — | Cardiac Allograft Vasculopathy | Withdrawn | 2025-12-01 | 2030-06-01 | ClinicalTrials.gov |
| NCT07084558 | ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tu… | Na | Early and Locally Advanced Breast Cancer | Recruiting | 2025-08-13 | 2033-06-30 | ClinicalTrials.gov |
| NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study | — | Breast Cancer | Recruiting | 2025-07-21 | 2035-01-01 | ClinicalTrials.gov |
| NCT07046585 | Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Po… | — | Colo-rectal Cancer | Recruiting | 2025-05-30 | 2033-09-30 | ClinicalTrials.gov |
| NCT06529822 | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Mo… | Phase1 | Muscle-Invasive Bladder Carcinoma | Recruiting | 2025-03-20 | 2033-03-31 | ClinicalTrials.gov |
| NCT06854939 | A Prospective Study Investigating the Relationship Between Minimal Residual Dis… | — | NSCLC, Stage I, II, III | Not_Yet_Recruiting | 2025-03-01 | 2029-09-30 | ClinicalTrials.gov |
| NCT06613516 | Effect of Capivasertib on ctDNA in ER Positive Breast Cancer | Phase2 | Breast Cancer | Withdrawn | 2025-02-01 | 2025-09-16 | ClinicalTrials.gov |
| NCT06450314 | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable… | Phase2 | Metastatic Breast Cancer | Recruiting | 2025-01-25 | 2029-12-15 | ClinicalTrials.gov |
| NCT06414603 | A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Sur… | Na | Heart Transplant Failure and Rejection | Active_Not_Recruiting | 2024-06-10 | 2027-02-01 | ClinicalTrials.gov |
| NCT05965479 | Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer | Phase2 | Gastrooesophageal Cancer | Recruiting | 2024-04-10 | 2028-04-30 | ClinicalTrials.gov |
| NCT06620627 | Prospective Collection of Samples to Enable the Development of Natera Screening… | — | Colorectal Cancer Screening | Recruiting | 2024-01-26 | 2025-10-31 | ClinicalTrials.gov |
| NCT06808880 | EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) | — | Single Gene NIPT | Recruiting | 2024-01-25 | 2027-12-01 | ClinicalTrials.gov |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (T… | Phase3 | ER-positive Breast Cancer | Recruiting | 2023-12-15 | 2035-11-01 | ClinicalTrials.gov |
| NCT05837663 | Trifecta-Lung cfDNA-MMDx Study | — | Lung Transplantation | Recruiting | 2023-11-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT05058183 | Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer | Na | Breast Cancer | Recruiting | 2023-06-05 | 2028-12-05 | ClinicalTrials.gov |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers | Phase3 | Colon Adenocarcinoma | Recruiting | 2023-03-29 | 2028-12-01 | ClinicalTrials.gov |
| NCT05081739 | Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation | Na | Heart Transplant Failure and Rejection | Withdrawn | 2023-01-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT05309382 | Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart … | — | Heart Transplant | Completed | 2022-12-12 | 2024-10-02 | ClinicalTrials.gov |
| NCT05170425 | LAMBDA 002 (Lung Registry) Study | — | Lung Transplant Rejection | Active_Not_Recruiting | 2022-11-04 | 2027-05-01 | ClinicalTrials.gov |
| NCT05379907 | Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic… | — | Pancreatic Cancer | Withdrawn | 2022-08-23 | 2023-08-23 | ClinicalTrials.gov |
| NCT05366829 | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carc… | Phase2 | Carcinoma, Hepatocellular | Recruiting | 2022-07-25 | 2027-06-01 | ClinicalTrials.gov |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase2 | Stage III Colon Cancer | Recruiting | 2022-07-08 | 2030-03-10 | ClinicalTrials.gov |
| NCT05178576 | A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients … | Phase2 | Colon Cancer | Withdrawn | 2022-06-24 | 2027-02-01 | ClinicalTrials.gov |
| NCT05052671 | ctDNA Assay in Patients With Resectable Pancreatic Cancer | — | Pancreas Cancer | Recruiting | 2022-05-25 | 2028-12-01 | ClinicalTrials.gov |
| NCT05914792 | Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit… | — | Breast Cancer | Active_Not_Recruiting | 2022-04-19 | 2026-07-01 | ClinicalTrials.gov |
| NCT04786600 | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refracto… | Phase2 | Metastatic Colorectal Cancer | Terminated | 2022-03-14 | 2024-03-19 | ClinicalTrials.gov |
| NCT06476717 | Donor-derived Cell-free DNA in Kidney Transplant Recipients | — | Kidney Transplantation | Completed | 2021-10-21 | 2024-05-20 | ClinicalTrials.gov |
| NCT05205551 | Prospera Test Evaluation in Cardiac Transplant (ProTECT) | — | Heart Transplant Rejection | Active_Not_Recruiting | 2021-10-01 | 2027-06-30 | ClinicalTrials.gov |
| NCT05312814 | Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in … | — | Twin to Twin Transfusion Syndrome | Completed | 2021-10-01 | 2023-05-15 | ClinicalTrials.gov |
| NCT05081024 | Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patien… | — | Rectal Adenocarcinoma | Recruiting | 2021-09-03 | 2026-09-03 | ClinicalTrials.gov |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in C… | Phase1 | Colon Adenocarcinoma | Recruiting | 2021-08-26 | 2028-01-21 | ClinicalTrials.gov |
| NCT05175235 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI P… | Phase1 | Solid Tumor | Unknown | 2021-08-19 | 2023-08-01 | ClinicalTrials.gov |
| NCT05004337 | Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Va… | — | Vanishing Twin | Completed | 2021-07-22 | 2023-11-29 | ClinicalTrials.gov |
| NCT05846113 | Renasight Clinical Application, Review and Evaluation (RenaCARE) Study | Na | Kidney Diseases | Unknown | 2021-06-07 | 2025-08-01 | ClinicalTrials.gov |
| NCT04707872 | Trifecta-Heart cfDNA-MMDx Study | — | Heart Transplant Rejection | Recruiting | 2021-06-01 | 2028-07-01 | ClinicalTrials.gov |
| NCT04761783 | BESPOKE Study of ctDNA Guided Immunotherapy | — | Colorectal Cancer | Completed | 2021-05-28 | 2024-03-30 | ClinicalTrials.gov |
| NCT04660344 | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With… | Phase3 | Muscle-invasive Bladder Cancer | Active_Not_Recruiting | 2021-05-03 | 2026-10-01 | ClinicalTrials.gov |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment o… | Phase1 | Locally Advanced Rectal Carcinoma | Recruiting | 2021-02-11 | 2027-10-15 | ClinicalTrials.gov |
| NCT05736523 | Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ct… | — | Melanoma | Active_Not_Recruiting | 2020-09-23 | 2025-06-01 | ClinicalTrials.gov |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | — | Biliary Tract Cancer | Terminated | 2020-07-08 | 2025-04-04 | ClinicalTrials.gov |
| NCT04264702 | BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer | — | Colorectal Cancer | Unknown | 2020-04-24 | 2025-09-01 | ClinicalTrials.gov |
| NCT04239703 | Trifecta-Kidney cfDNA-MMDx Study | — | Kidney Transplant Rejection | Recruiting | 2019-12-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT04091984 | The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) | — | Kidney Transplant Rejection | Active_Not_Recruiting | 2019-11-06 | 2027-10-01 | ClinicalTrials.gov |
| NCT03765203 | Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Pati… | Na | Transplant;Failure,Kidney | Completed | 2018-11-05 | 2019-01-07 | ClinicalTrials.gov |
| NCT03984747 | Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell… | — | Transplant Rejection | Completed | 2018-09-14 | 2024-08-23 | ClinicalTrials.gov |
| NCT03485651 | Natera Ovarian Cancer Detection Assay | — | Adnexal Mass | Terminated | 2017-12-14 | 2019-12-31 | ClinicalTrials.gov |
| NCT02381457 | SNP-based Microdeletion and Aneuploidy RegisTry (SMART) | — | 22q11 Deletion Syndrome | Completed | 2015-04-01 | 2020-06-01 | ClinicalTrials.gov |
| NCT02278874 | High Risk Multiple Gestation Study | — | Trisomy 13 | Completed | 2014-08-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT01966991 | Prenatal Screening for Down Syndrome With DNAFirst | — | Trisomy 21 | Completed | 2014-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02278536 | Multiple Gestation Study | — | Trisomy 13 | Completed | 2013-03-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT01852708 | Development of Non-invasive Prenatal Screening Test for Microdeletions Based on… | — | Trisomy 21 | Completed | 2012-11-01 | 2020-10-01 | ClinicalTrials.gov |
| NCT02109770 | Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic S… | — | Microdeletion Syndromes | Completed | 2012-10-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01663584 | Multi-disease Carrier Screening Test Validation | — | Spinal Muscular Atrophy (SMA) | Withdrawn | 2012-08-01 | — | ClinicalTrials.gov |
| NCT01546324 | Collection of Maternal Blood Samples for Development of Non-invasive Prenatal D… | — | Pregnancy Following IVF With PGS/PGD | Completed | 2012-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01545674 | Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial | — | Trisomy 13 | Terminated | 2012-01-01 | 2023-03-01 | ClinicalTrials.gov |
| NCT01574781 | Non-invasive Prenatal Diagnostic Validation Study | — | Chromosome 13 Aneuploidy | Completed | 2011-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01194531 | Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplant… | Phase4 | Preimplantation Gentic Screening (PGS) | Terminated | 2010-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01197872 | Clinical Use of Parental Support To Detect Single Gene Mutations | — | Single Gene Disorders | Completed | 2010-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01023048 | Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Dia… | Na | Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs) | Completed | 2009-11-01 | 2014-03-01 | ClinicalTrials.gov |
Total clinical trials: 69
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| HLA antibody | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| Prospera | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| MMDx diagnostic test | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| HLA antibody | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT04239703 |
| Prospera | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT04239703 |
| MMDx | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT04239703 |
| HLA antibody | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| Prospera | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| MMDx diagnostic test | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Exemestane 25 MG | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Anastrozole 1mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Letrozole 2.5mg | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Tamoxifen | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Elacestrant | Other | Phase PHASE3 | ER-positive Breast Cancer | RECRUITING | NCT05512364 |
| Signatera MRD ctDNA Assay | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Standard Treatment | Drug | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Irinotecan | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Signatera MRD ctDNA Assay | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Standard Treatment | Drug | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Irinotecan | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Signatera MRD ctDNA Assay | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Standard Treatment | Drug | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Irinotecan | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Signatera MRD ctDNA Assay | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Standard Treatment | Drug | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Irinotecan | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Signatera MRD ctDNA Assay | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Standard Treatment | Drug | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Irinotecan | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Signatera MRD ctDNA Assay | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Standard Treatment | Drug | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Irinotecan | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | RECRUITING | NCT07401316 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Gastric-Esophageal Cancer | NOT_YET_RECRUITING | NCT07565857 |
| Signatera test | Other | Phase PHASE2 | Colon Cancer | WITHDRAWN | NCT05178576 |
| Gevokizumab | Other | Phase PHASE2 | Colon Cancer | WITHDRAWN | NCT05178576 |
| Nivolumab, Pembrolizumab | Other | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT05175235 |
| CURATE.AI | Other | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT05175235 |
| Blood Draw | Other | Preclinical | Trisomy 13 | TERMINATED | NCT01545674 |
| ctDNA | Other | Approved | Breast Cancer | RECRUITING | NCT05058183 |
| Cheek swab/Saliva Sampling | Other | Preclinical | Chromosome 13 Aneuploidy | COMPLETED | NCT01574781 |
| Blood draw | Other | Preclinical | Chromosome 13 Aneuploidy | COMPLETED | NCT01574781 |
| Blood draw | Other | Preclinical | Spinal Muscular Atrophy (SMA) | WITHDRAWN | NCT01663584 |
| Preimplantation Genetic Diagnosis | Other | Preclinical | Single Gene Disorders | COMPLETED | NCT01197872 |
| Blood draw | Other | Preclinical | Pregnancy Following IVF With PGS/PGD | COMPLETED | NCT01546324 |
| preimplantation diagnosis | Other | Approved | Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs) | COMPLETED | NCT01023048 |
| 24 Chromosome Aneuploidy Screening with Parental Support | Other | Phase PHASE4 | Preimplantation Gentic Screening (PGS) | TERMINATED | NCT01194531 |
| Clinical Performance and Value Vignettes | Other | Approved | Transplant;Failure,Kidney | COMPLETED | NCT03765203 |
| Natera KidneyScan | Other | Approved | Transplant;Failure,Kidney | COMPLETED | NCT03765203 |
| SIGNATERA™ ctDNA testing | Other | Preclinical | Pancreatic Cancer | WITHDRAWN | NCT05379907 |
| Renasight | Other | Approved | Kidney Diseases | UNKNOWN | NCT05846113 |
| Endomyocardial biopsy | Other | Approved | Heart Transplant Failure and Rejection | WITHDRAWN | NCT05081739 |
| Prospera Transplant Assessment | Other | Approved | Heart Transplant Failure and Rejection | WITHDRAWN | NCT05081739 |
| Prospera | Other | Preclinical | Kidney Transplant Rejection | ACTIVE_NOT_RECRUITING | NCT04091984 |
| Prospera | Other | Preclinical | Heart Transplant | COMPLETED | NCT05309382 |
| Trastuzumab deruxtecan | Other | Phase PHASE2 | Gastrooesophageal Cancer | RECRUITING | NCT05965479 |
| Monitoring with signatera test | Other | Phase PHASE2 | Metastatic Breast Cancer | RECRUITING | NCT06450314 |
| Discontinuation of the anti-HER2 maintenance therapy | Drug | Phase PHASE2 | Metastatic Breast Cancer | RECRUITING | NCT06450314 |
| Antirejection therapy | Drug | Preclinical | Kidney Transplantation | COMPLETED | NCT06476717 |
| Blood Biomarkers - cfDNA | Other | Preclinical | Kidney Transplantation | COMPLETED | NCT06476717 |
| Biopsy | Other | Preclinical | Kidney Transplantation | COMPLETED | NCT06476717 |
| Bevacizumab | Other | Phase PHASE3 | Colon Adenocarcinoma | RECRUITING | NCT05482516 |
| Atezolizumab | Other | Phase PHASE3 | Colon Adenocarcinoma | RECRUITING | NCT05482516 |
| Prospera | Other | Preclinical | Lung Transplant Rejection | ACTIVE_NOT_RECRUITING | NCT05170425 |
| pre-specified sequence of FDA-approved drugs and drug combinations | Drug | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04786600 |
| Signatera ctDNA assay | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04786600 |
| Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring | Drug | Preclinical | Biliary Tract Cancer | TERMINATED | NCT04561453 |
| HLA antibody | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT04239703 |
| Prospera | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT04239703 |
| MMDx | Other | Preclinical | Kidney Transplant Rejection | RECRUITING | NCT04239703 |
| ctDNA-Guided Treatment Strategy | Drug | Approved | Breast Neoplasms | RECRUITING | NCT07214532 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Electronic Health Record Review | Other | Preclinical | Rectal Adenocarcinoma | RECRUITING | NCT05081024 |
| Biospecimen Collection | Other | Preclinical | Rectal Adenocarcinoma | RECRUITING | NCT05081024 |
| Biopsy | Other | Preclinical | Rectal Adenocarcinoma | RECRUITING | NCT05081024 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | Other | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| FFPE tumor sample for Signatera (TM) test (archived) | Other | Approved | Early and Locally Advanced Breast Cancer | RECRUITING | NCT07084558 |
| biopsy for Ki-67 assessment | Other | Approved | Early and Locally Advanced Breast Cancer | RECRUITING | NCT07084558 |
| blood sample for Signatera (TM) test | Other | Approved | Early and Locally Advanced Breast Cancer | RECRUITING | NCT07084558 |
| Blood draw to measure the levels of dd-cf DNA | Other | Preclinical | Cardiac Allograft Vasculopathy | WITHDRAWN | NCT05756088 |
| Capivasertib | Other | Phase PHASE2 | Breast Cancer | WITHDRAWN | NCT06613516 |
| Signatera assay | Other | Phase PHASE1 | Muscle-Invasive Bladder Carcinoma | RECRUITING | NCT06529822 |
| Poly ICLC | Other | Phase PHASE1 | Muscle-Invasive Bladder Carcinoma | RECRUITING | NCT06529822 |
| Synthetic long peptide personalized cancer vaccine | Other | Phase PHASE1 | Muscle-Invasive Bladder Carcinoma | RECRUITING | NCT06529822 |
| Tislelizumab | Other | Phase PHASE2 | Carcinoma, Hepatocellular | RECRUITING | NCT05366829 |
| Pembrolizumab | Other | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT07183319 |
| Pembrolizumab & Enfortumab Vedotin (PEV) | Other | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT07183319 |
| Obstetrical carrier screening | Other | Approved | Hereditary Cancer Syndrome | RECRUITING | NCT07195071 |
| Natera empower comprehensive hereditary cancer panel | Other | Approved | Hereditary Cancer Syndrome | RECRUITING | NCT07195071 |
| The Prospera™ Test | Other | Approved | Heart Transplant Failure and Rejection | ACTIVE_NOT_RECRUITING | NCT06414603 |
| HLA antibody | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| Prospera | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| MMDx diagnostic test | Other | Preclinical | Heart Transplant Rejection | RECRUITING | NCT04707872 |
| Whole blood for ctDNA | Other | Approved | Germ Cell Cancer Metastatic | NOT_YET_RECRUITING | NCT07401316 |
| Signatera | Other | Phase PHASE3 | Muscle-invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04660344 |
| Placebo | Other | Phase PHASE3 | Muscle-invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04660344 |
| Atezolizumab | Other | Phase PHASE3 | Muscle-invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04660344 |
| Total Mesorectal Excision | Other | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Surveillance | Other | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Quality-of-Life Assessment | Other | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Oxaliplatin | Other | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Leucovorin | Other | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Intensity-Modulated Radiation Therapy | Drug | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Fluorouracil | Other | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Capecitabine | Other | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Signatera MRD ctDNA Assay | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Standard Treatment | Drug | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| Irinotecan | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | Other | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| CAPOX 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | Other | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| Signatera Genome ultra-sensitive ctDNA blood test | Other | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| FOLFOX regimen | DRUG | Phase PHASE3 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07340567 |
| Folfirinox | DRUG | Phase PHASE3 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07340567 |
| Signatera Genome ultra-sensitive ctDNA blood test | DEVICE | Approved | Endometrial Cancer | NOT_YET_RECRUITING | NCT07339384 |
| ctDNA-Guided Treatment Strategy | DEVICE | Approved | Breast Neoplasms | NOT_YET_RECRUITING | NCT07214532 |
| Obstetrical carrier screening | DEVICE | Approved | Hereditary Cancer Syndrome | RECRUITING | NCT07195071 |
| Natera empower comprehensive hereditary cancer panel | DEVICE | Approved | Hereditary Cancer Syndrome | RECRUITING | NCT07195071 |
| Pembrolizumab & Enfortumab Vedotin (PEV) | DRUG | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT07183319 |
| Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT) | PROCEDURE | Phase PHASE2 | Hodgkin Lymphoma, Adult | NOT_YET_RECRUITING | NCT07021989 |
| Pegfilgrastim | DRUG | Phase PHASE2 | Hodgkin Lymphoma, Adult | NOT_YET_RECRUITING | NCT07021989 |
| Foresight CLARITY™ LDT | DEVICE | Phase PHASE2 | Hodgkin Lymphoma, Adult | NOT_YET_RECRUITING | NCT07021989 |
| Liposomal Doxorubicin | DRUG | Phase PHASE2 | Hodgkin Lymphoma, Adult | NOT_YET_RECRUITING | NCT07021989 |
| Vinorelbine | DRUG | Phase PHASE2 | Hodgkin Lymphoma, Adult | NOT_YET_RECRUITING | NCT07021989 |
| Gemcitabine | DRUG | Phase PHASE2 | Hodgkin Lymphoma, Adult | NOT_YET_RECRUITING | NCT07021989 |
| Non-investigational, involved site radiotherapy (ISRT) | RADIATION | Phase PHASE2 | Hodgkin Lymphoma, Adult | NOT_YET_RECRUITING | NCT07021989 |
| Pembrolizumab | DRUG | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT07183319 |
| Single-gene Noninvasive Prenatal Testing (sgNIPT) | DEVICE | Preclinical | Single Gene NIPT | RECRUITING | NCT06808880 |
| Capivasertib | DRUG | Phase PHASE2 | Breast Cancer | WITHDRAWN | NCT06613516 |
| Signatera assay | DEVICE | Phase PHASE1 | Muscle-Invasive Bladder Carcinoma | RECRUITING | NCT06529822 |
| Poly ICLC | DRUG | Phase PHASE1 | Muscle-Invasive Bladder Carcinoma | RECRUITING | NCT06529822 |
| Synthetic long peptide personalized cancer vaccine | BIOLOGICAL | Phase PHASE1 | Muscle-Invasive Bladder Carcinoma | RECRUITING | NCT06529822 |
| Antirejection therapy | DRUG | Preclinical | Kidney Transplantation | COMPLETED | NCT06476717 |
| Monitoring with signatera test | DEVICE | Phase PHASE2 | Metastatic Breast Cancer | RECRUITING | NCT06450314 |
| Discontinuation of the anti-HER2 maintenance therapy | DRUG | Phase PHASE2 | Metastatic Breast Cancer | RECRUITING | NCT06450314 |
| Trastuzumab deruxtecan | DRUG | Phase PHASE2 | Gastrooesophageal Cancer | RECRUITING | NCT05965479 |
| Bevacizumab | DRUG | Phase PHASE3 | Colon Adenocarcinoma | RECRUITING | NCT05482516 |
| SIGNATERA™ ctDNA testing | OTHER | Preclinical | Pancreatic Cancer | WITHDRAWN | NCT05379907 |
| Tislelizumab | DRUG | Phase PHASE2 | Carcinoma, Hepatocellular | RECRUITING | NCT05366829 |
| Gevokizumab | DRUG | Phase PHASE2 | Colon Cancer | WITHDRAWN | NCT05178576 |
| Nivolumab, Pembrolizumab | DRUG | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT05175235 |
| CURATE.AI | DEVICE | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT05175235 |
| CAPOX 6 month | DRUG | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 6 month | DRUG | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFIRINOX | DRUG | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| CAPOX 3 month | DRUG | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| mFOLFOX6 3-6 month | DRUG | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Signatera test | DEVICE | Phase PHASE2 | Stage III Colon Cancer | RECRUITING | NCT05174169 |
| Prospera | DEVICE | Preclinical | Lung Transplant Rejection | ACTIVE_NOT_RECRUITING | NCT05170425 |
| Endomyocardial biopsy | PROCEDURE | Approved | Heart Transplant Failure and Rejection | WITHDRAWN | NCT05081739 |
| Electronic Health Record Review | OTHER | Preclinical | Rectal Adenocarcinoma | RECRUITING | NCT05081024 |
| Biospecimen Collection | PROCEDURE | Preclinical | Rectal Adenocarcinoma | RECRUITING | NCT05081024 |
| Biopsy | PROCEDURE | Preclinical | Kidney Transplantation | COMPLETED | NCT06476717 |
| Irinotecan | DRUG | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| TAS-102 | DRUG | Phase PHASE1 | Colon Adenocarcinoma | RECRUITING | NCT04920032 |
| pre-specified sequence of FDA-approved drugs and drug combinations | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04786600 |
| Signatera ctDNA assay | DEVICE | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04786600 |
| Total Mesorectal Excision | PROCEDURE | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Surveillance | BEHAVIORAL | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Quality-of-Life Assessment | OTHER | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Oxaliplatin | DRUG | Phase PHASE3 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07340567 |
| Leucovorin | DRUG | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Intensity-Modulated Radiation Therapy | RADIATION | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Fluorouracil | DRUG | Phase PHASE1 | Locally Advanced Rectal Carcinoma | RECRUITING | NCT04703101 |
| Capecitabine | DRUG | Phase PHASE3 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07340567 |
| Signatera | DEVICE | Phase PHASE3 | Muscle-invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04660344 |
| Placebo | OTHER | Phase PHASE3 | Muscle-invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04660344 |
| Atezolizumab | DRUG | Phase PHASE3 | Colon Adenocarcinoma | RECRUITING | NCT05482516 |
| Clinical Performance and Value Vignettes | OTHER | Approved | Transplant;Failure,Kidney | COMPLETED | NCT03765203 |
| Cheek swab/Saliva Sampling | PROCEDURE | Preclinical | Chromosome 13 Aneuploidy | COMPLETED | NCT01574781 |
| Blood Draw | PROCEDURE | Preclinical | Trisomy 13 | TERMINATED | NCT01545674 |
| 24 Chromosome Aneuploidy Screening with Parental Support | DEVICE | Phase PHASE4 | Preimplantation Gentic Screening (PGS) | TERMINATED | NCT01194531 |
| Blood draw | PROCEDURE | Preclinical | Spinal Muscular Atrophy (SMA) | WITHDRAWN | NCT01663584 |
| Preimplantation Genetic Diagnosis | OTHER | Preclinical | Single Gene Disorders | COMPLETED | NCT01197872 |
| preimplantation diagnosis | OTHER | Approved | Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs) | COMPLETED | NCT01023048 |
Total products: 425